Serotonin receptor 3A, 3B, 3C, 3D, and 3E (5-HT₃ receptor (subunits: 5-HT₃A, 5-HT₃B, 5-HT₃C, 5-HT₃D, and 5-HT₃E))

The **serotonin type three receptors**, encoded by five human genes (**HTR3A-E**) corresponding to subunits A through E, form pentameric ligand-gated ion channels distinct from other serotonin receptors which are G protein-coupled. These receptors mediate fast excitatory neurotransmission upon activation by serotonin. They play a key role in regulating gastrointestinal function—especially emesis—and modulate central nervous system development by influencing interneuron migration and synaptic network formation. Clinically important as targets for antiemetic drugs like ondansetron used during cancer therapy or surgery, they have also been implicated via genetic studies in psychiatric conditions such as anxiety disorders and potentially autism spectrum disorder. Only subtypes A–E exist; designations T/X/Y/Z do not correspond to any known human gene products.[1][4][7]

Other names

Serotonin-gated ion channelSerotonin type 3 receptorSerotonin-gated cation channelHTR3A/B/C/D/E (gene symbols)5-hydroxytryptamine receptor type 3

Drugs targeting this molecule typically act as **antagonists**, blocking serotonin binding at the ligand-gated ion channel to inhibit downstream signaling involved in emesis pathways. This reduces stimulation of vagal afferents that trigger vomiting reflexes during chemotherapy or other triggers.[1][4] Some research explores agonist activity for potential neurodevelopmental modulation but clinical use is almost exclusively antagonistic.